U.S. markets close in 5 hours 24 minutes

Altimmune, Inc. (ALT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.7291-0.0909 (-1.89%)
As of 10:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.8200
Bid4.7900 x 1200
Ask4.8000 x 900
Day's Range4.7100 - 4.9700
52 Week Range3.8300 - 23.4900
Avg. Volume1,823,705
Market Cap233.045M
Beta (5Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-2.0800
Earnings DateMay 10, 2023 - May 15, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJan 20, 2017
1y Target Est26.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ALT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Altimmune, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.
    Fair Value
    Economic Moat
    23 hours agoMorningstar
View more
  • GlobeNewswire

    Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors

    GAITHERSBURG, Md., March 27, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the appointment of Catherine Angell Sohn, Pharm.D. to its Board of Directors. “We are delighted to welcome Catherine to our Board of Directors,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer. “Her broad experience in the pharmaceutical industry including strategic product development, business development and commercialization will be

  • GlobeNewswire

    Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial

    MOMENTUM Phase 2 Obesity Trial (Week 24 Interim Analysis of 160 Subjects) Mean weight loss of 10.7% (placebo-adjusted 9.7%) at 2.4 mg dose at Week 24Mean weight loss of 11.9% (placebo-adjusted 11.1%) in subjects weighing 115 kg or less at baseline at 2.4 mg dose at Week 24Approximately 50% of subjects achieved 10% or more weight loss and approximately 20% of subjects achieved 15% or more weight loss at the 1.8 mg and 2.4 mg doses at Week 24Robust reductions in waist circumference, serum lipids a

  • GlobeNewswire

    Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update

    Interim 24-week readout from MOMENTUM Phase 2 obesity trial expected March 2023 Initiation of Phase 2b non-alcoholic steatohepatitis (NASH) trial expected mid-2023 Webcast to be held today, February 28, 2023, at 8:30 am ET GAITHERSBURG, Md., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “The next twelve-mont